Dr. Rampal on Ongoing Research With Pacritinib in Myelofibrosis | OncLive

Dr. Rampal on Ongoing Research With Pacritinib in Myelofibrosis

January 24, 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.

Several JAK inhibitors are in development in myelofibrosis, one of which is pacritinib. Pacritinib is under evaluation, specifically in patients with myelofibrosis who have low platelets, says Rampal. A study evaluating the use of pacritinib was recently completed, and data from that trial are anticipated to read out in the near future.

In addition, there is a planned phase III trial that will look at pacritinib versus investigator’s choice for patients with low platelets. This will be an important study, if positive, because there is currently no standard of care for patients with platelets below 50,000 per microliter, concludes Rampal.


x